FDA 483 - Zydus Lifesciences Limited - May 05, 2026

Between April 27 and May 5, 2026, the U.S. Food and Drug Administration (FDA) conducted an inspection of the Zydus Lifesciences Limited sterile manufacturing facility located in Ahmedabad, India. This inspection resulted in an FDA Form 483 identifying seven primary areas of concern regarding compliance with quality and safety standards. Major violations included a failure to investigate significant discrepancies in air velocity during equipment qualification and a lack of oversight regarding physical defects in sterile processing areas. Specifically, investigators observed residues and cracks within restricted access barrier systems, along with stained and peeling surfaces in cleanrooms that could compromise sterility. Furthermore, the firm’s environmental monitoring program was deemed insufficient due to vague sampling instructions and inadequate tracking of ancillary equipment. Technical deficiencies were also noted in sterilization validation, where airflow visualization studies revealed turbulence and failed to demonstrate unidirectional flow. Additionally, the facility lacked proper controls over electronic data, as quality assurance personnel were releasing drug products based on paper printouts rather than reviewing comprehensive electronic audit trails. Under the FDA regulatory framework, these observations indicate a need for immediate improvement in production and process controls. Zydus Lifesciences is required to respond to these findings by detailing implemented or planned corrective actions. Failure to address these deficiencies effectively may lead to further regulatory enforcement actions to ensure the safety and purity of drug products intended for the U.S. market.